This trial was designed to address important issues that impact recipients of liver allografts as well as clinicians, ie, renal function, reduction or discontinuation of tacrolimus early post-transplantation, and progression rate of fibrosis in hepatitis C virus (HCV) positive patients.
A new study published in the journal Clinical Chemistry reported Architect Tacrolimus assay from Abbott Diagnostics provides accurate and consistent...
Veloxis Pharmaceuticals A/S announced FDA approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant...
Veloxis Pharmaceuticals has announced that once-daily Envarsus XR (tacrolimus extended-release), for the prevention of organ rejection in adult kidney transplant...
Prophylaxis of transplant rejection in liver, kidney or heart allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.
Prophylaxis of transplant rejection in adult and paediatric, kidney, liver or heart allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult and paediatric patients.